Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 3/20 | 0.39 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.36 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.36 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.36 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | ADRB2 | P07550 | 4/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | MAOA | P21397 | 2/20 | 0.34 |
| ▸ | APP | P05067 | 1/20 | 0.34 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.34 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2977115 | 0.85 | MAOB (0.38) | MAOBADRA2AADRA2BADRA2CABHD6 | |
| SCHEMBL27984245 | 0.83 | TAAR1 (0.44) | MAOBADRA2AADRA2BADRA2CCYP2D6 | |
| SCHEMBL11210106 | 0.76 | MAOB (0.47) | MAOBABHD6TP53CYP3A4ADRB2 | |
| SCHEMBL2977768 | 0.74 | TAAR1 (0.42) | ADRA2AADRA2BADRA2CTP53CYP3A4 | |
| SCHEMBL2976805 | 0.73 | PRKCI (0.44) | — | |
| SCHEMBL18217414 | 0.73 | MAOB (0.47) | MAOBABHD6TP53CYP3A4ADRB2 | |
| SCHEMBL2659958 | 0.71 | PRKCI (0.35) | — | |
| SCHEMBL14886811 | 0.71 | MAOB (0.42) | MAOBABHD6TP53CYP3A4ADRB2 | |
| Trifluoroacetic Acid SCHEMBL6220279 | 0.71 | ADRA2A (0.39) | ADRA2AADRA2BADRA2CCYP3A4ADRB2 | |
| SCHEMBL14752978 | 0.70 | TXN (0.39) | ADRA2AADRA2BADRA2CCYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7776900-B2 | Benzimidazole derivatives and their use for modulating the GABAAreceptor complex | NEUROSEARCH A/S (DK) | 2010-08-17 | — | — | US | disclosed |
| US-20090030018-A1 | Benzimidazole derivatives and their use for modulating the gabaalpha receptor complex | ANIONA APS (DK) | 2009-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090030018-A1 | Benzimidazole derivatives and their use for modulating the gabaalpha receptor complex | GABRB2, GABRB1, GABRB3 | MAOB 164/4885ADRA2A 126/4885ADRA2B 112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.